BMS-986177 + aspirin + clopidogrel

BMS-986177 + aspirin + clopidogrel is a **combination pharmacological regimen** consisting of milvexian (BMS-986177), a small molecule, oral, direct **Factor XIa inhibitor**, with dual antiplatelet therapy using **aspirin** and **clopidogrel**. Milvexian, developed by Bristol Myers Squibb in collaboration with Janssen Pharmaceuticals, acts by selectively inhibiting the active site of Factor XIa to reduce thrombin generation and subsequent clot formation. Aspirin is an antiplatelet agent that irreversibly inhibits cyclooxygenase (COX-1), thereby decreasing thromboxane A2 and platelet aggregation. Clopidogrel is an antiplatelet drug that inhibits the P2Y12 adenosine diphosphate receptor on platelet cell membranes to further prevent aggregation. This combination is under clinical investigation for the **prevention of new ischemic stroke or covert brain infarction** in patients with recent acute ischemic stroke or transient ischemic attack, as secondary prevention, by targeting multiple pathways in thrombus formation[1][2][4][5].

Other names

milvexian + aspirin + clopidogrel